Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2026/04/08

The report presents the governance structure of a company with an Audit & Supervisory Committee, including the Nomination and Compensation Committee, Risk Management Committee, Compliance Committee and Sustainability Committee, as well as skills information for directors and executive officers. The body of the report does not specify any changes from the previous report.

Worth reading
73In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors11 directors (including 5 outside directors)
Committee3
Nomination and Compensation CommitteeRisk Management CommitteeCompliance Committee and Sustainability Committee. The proportion of outside committee members is 非開示
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors11 directors (including 5 outside directors)
CommitteeNomination and Compensation Committee, Risk Management Committee, Compliance Committee and Sustainability Committee. The proportion of outside committee members is Not disclosed
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/04/08 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori